Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

7/11/24 9:01:05 AM ET

$MYGN

$PSNL

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Medical Specialities

Health Care

Get the next $MYGN alert in real time by email

Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

Get the next $MYGN alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$MYGN
$PSNL

Company	Date	Price Target	Rating	Analyst
Personalis Inc. $PSNL	12/2/2025	$11.00	Equal-Weight	Morgan Stanley
Myriad Genetics Inc. $MYGN	5/21/2025	$6.00	Sector Outperform → Sector Perform	Scotiabank
Personalis Inc. $PSNL	5/15/2025	$6.00	Buy	Guggenheim
Myriad Genetics Inc. $MYGN	5/8/2025		Outperform → Peer Perform	Wolfe Research
Myriad Genetics Inc. $MYGN	5/7/2025	$6.00	Overweight → Equal Weight	Wells Fargo
Myriad Genetics Inc. $MYGN	4/9/2025		Buy → Neutral	Guggenheim
Personalis Inc. $PSNL	3/17/2025	$8.00	Buy	Canaccord Genuity
Myriad Genetics Inc. $MYGN	3/12/2025	$11.50 → $12.50	Neutral → Overweight	Piper Sandler

More analyst ratings

Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$MYGN
$PSNL

Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$MYGN
$PSNL

$MYGN
$PSNL
SEC Filings

SEC Form DEFA14A filed by Personalis Inc.

SEC Form DEF 14A filed by Personalis Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Myriad Genetics Inc.

$MYGN
$PSNL
Insider Trading

SEC Form 4 filed by Verratti Mark

SEC Form 4 filed by Muzzey Dale

SEC Form 4 filed by Wheeler Benjamin Richard

$MYGN
$PSNL
Insider Purchases

President and CEO Raha Samraat S. bought $199,844 worth of shares (40,000 units at $5.00), increasing direct ownership by 9% to 493,104 units (SEC Form 4)

Director Phanstiel S. Louise bought $494,722 worth of shares (104,507 units at $4.73), increasing direct ownership by 59% to 281,951 units (SEC Form 4)

Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

$MYGN
$PSNL
Press Releases

Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

Personalis to Participate in the 25th Annual Needham Virtual Conference

$MYGN
$PSNL
Analyst Ratings

Morgan Stanley resumed coverage on Personalis with a new price target

Myriad Genetics downgraded by Scotiabank with a new price target

Guggenheim initiated coverage on Personalis with a new price target

$MYGN
$PSNL
Financials

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

$MYGN
$PSNL
Leadership Updates

Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

Diality Appoints Peter Donato as Chief Financial Officer

$MYGN
$PSNL
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

Amendment: SEC Form SC 13G/A filed by Personalis Inc.

SEC Form SC 13G filed by Personalis Inc.

Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $MYGN$PSNL

Myriad Genetics And Personalis Announce Cross-Licensing Agreement For Tumor-Informed MRD Detection Patents; Agreement Enhances Freedom To Operate In MRD Market And Broadens Patient Access To MRD Testing Benefits

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $MYGN$PSNL

$MYGN$PSNL SEC Filings

SEC Form DEFA14A filed by Personalis Inc.

SEC Form DEF 14A filed by Personalis Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Myriad Genetics Inc.

$MYGN$PSNL Insider Trading

SEC Form 4 filed by Verratti Mark

SEC Form 4 filed by Muzzey Dale

SEC Form 4 filed by Wheeler Benjamin Richard

$MYGN$PSNL Insider Purchases

President and CEO Raha Samraat S. bought $199,844 worth of shares (40,000 units at $5.00), increasing direct ownership by 9% to 493,104 units (SEC Form 4)

Director Phanstiel S. Louise bought $494,722 worth of shares (104,507 units at $4.73), increasing direct ownership by 59% to 281,951 units (SEC Form 4)

Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

$MYGN$PSNL Press Releases

Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

Personalis to Participate in the 25th Annual Needham Virtual Conference

$MYGN$PSNL Analyst Ratings

Morgan Stanley resumed coverage on Personalis with a new price target

Myriad Genetics downgraded by Scotiabank with a new price target

Guggenheim initiated coverage on Personalis with a new price target

$MYGN$PSNL Financials

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

$MYGN$PSNL Leadership Updates

Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

Diality Appoints Peter Donato as Chief Financial Officer

$MYGN$PSNL Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

Amendment: SEC Form SC 13G/A filed by Personalis Inc.

SEC Form SC 13G filed by Personalis Inc.

Recent Analyst Ratings for
$MYGN
$PSNL

Recent Analyst Ratings for
$MYGN
$PSNL

$MYGN
$PSNL
SEC Filings

$MYGN
$PSNL
Insider Trading

$MYGN
$PSNL
Insider Purchases

$MYGN
$PSNL
Press Releases

$MYGN
$PSNL
Analyst Ratings

$MYGN
$PSNL
Financials

$MYGN
$PSNL
Leadership Updates

$MYGN
$PSNL
Large Ownership Changes